Hunan Jiudian Pharmaceutical Co., Ltd.

300705

CNE1000034Z6

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 28/05/2024 am IST			5-day change	1st Jan Change
25.12 ^CNY	-1.72%		-3.36%	+5.83%

25/04	Hunan Jiudian Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023	CI
24/04	Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Hunan Jiudian Pharmaceutical's Shareholders and Parties Acting in Concert Plan to Cut Stake

November 05, 2020 at 05:29 pm IST

Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) said shareholders and parties acting in concert plan to cut up to a combined 5% stakes in the Company.

Latest news about Hunan Jiudian Pharmaceutical Co., Ltd.

Hunan Jiudian Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023	25/04	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	24/04	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Elects Yang Yang and Fan Pengyun as Non-Independent Director	27/01	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23/23/23	CI
Hunan Jiudian Pharmaceutical Co., Ltd.(XSEC:300705) added to S&P Global BMI Index	18/23/18	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	15/23/15	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Approves 2022 Final Profit Distribution, Payable on May 15, 2023	10/23/10	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	26/23/26	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Proposes Cash Dividend for the Year of 2022	18/23/18	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	14/23/14	CI
Hunan Jiudian Pharma Wins Nod to Trial Anti-Inflammatory Patch	05/23/05	MT
Jiudian Pharma Sees FY22 Profit to Rise Up to 33.7%	16/23/16	MT
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/22/27	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	30/22/30	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Announces Cash Dividend for A Shares for the Year 2021, Payable on 27 May 2022	21/22/21	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021	19/22/19	CI
Nan Jiudian Pharmaceutical Announces Profit Distribution Plan for 2021	28/22/28	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	26/22/26	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	26/22/26	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	25/21/25	CI
Hunan Jiudian Pharmaceutical Co., Ltd. entered into an agreement to acquire Hunan Huiyang Information Technology Co., Ltd. from Duan Lixin and Duan Linong for CNY 8.56 million.	10/21/10	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	09/21/09	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Approves Final Dividend for the Year 2020	11/21/11	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Announces Earnings Results for the First Quarter Ended March 31, 2021	28/21/28	CI
Hunan Jiudian Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year 2020	20/21/20	CI

Chart Hunan Jiudian Pharmaceutical Co., Ltd.

Duration

Period

Chart Hunan Jiudian Pharmaceutical Co., Ltd.

More charts

Hunan Jiudian Pharmaceutical Co Ltd is a company mainly engaged in research and development, production and sales of pharmaceutical preparations. The Companyâs products are comprised of pharmaceutical preparations, raw materials, pharmaceutical excipients and plant extracts, including loxoprofen sodium gel ointment, ornidazole raw materials and preparations, dirithromycin raw materials and preparations, clindamycin phosphate tablets and so on. The products are used for the treatment of bacterial infections and anti-allergy. The Company sells its products to both domestic and international markets, including Europe, South Korea, India, Russia and South America.

Sector

Pharmaceuticals

Calendar

22/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Hunan Jiudian Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

25.12

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HUNAN JIUDIAN PHARMACEUTICAL CO., LTD.	+5.83%	1.71B
ELI LILLY AND COMPANY	+38.59%	727B
JOHNSON & JOHNSON	-7.89%	354B
MERCK & CO., INC.	+15.66%	328B
ABBVIE INC.	+0.24%	277B
ASTRAZENECA PLC	+13.47%	243B
NOVARTIS AG	+7.35%	205B
ROCHE HOLDING AG	-6.42%	203B
AMGEN INC.	+4.23%	164B
PFIZER, INC.	-1.70%	164B

Other Pharmaceuticals

Hunan Jiudian Pharmaceutical Co., Ltd.

Equities

300705

CNE1000034Z6

Pharmaceuticals

Hunan Jiudian Pharmaceutical's Shareholders and Parties Acting in Concert Plan to Cut Stake

Latest news about Hunan Jiudian Pharmaceutical Co., Ltd.

Chart Hunan Jiudian Pharmaceutical Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Hunan Jiudian Pharmaceutical Co., Ltd.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals